Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to $2.0 million.

  • Adma Biologics' Depreciation & Amortization (CF) rose 427.84% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year decrease of 263.09%. This contributed to the annual value of $8.0 million for FY2024, which is 344.46% down from last year.
  • Per Adma Biologics' latest filing, its Depreciation & Amortization (CF) stood at $2.0 million for Q3 2025, which was up 427.84% from $2.1 million recorded in Q2 2025.
  • Adma Biologics' 5-year Depreciation & Amortization (CF) high stood at $2.1 million for Q1 2024, and its period low was $1.2 million during Q1 2021.
  • Over the past 5 years, Adma Biologics' median Depreciation & Amortization (CF) value was $1.9 million (recorded in 2024), while the average stood at $1.8 million.
  • As far as peak fluctuations go, Adma Biologics' Depreciation & Amortization (CF) soared by 5587.84% in 2021, and later crashed by 782.36% in 2024.
  • Adma Biologics' Depreciation & Amortization (CF) (Quarter) stood at $1.5 million in 2021, then grew by 27.55% to $1.9 million in 2022, then grew by 8.91% to $2.1 million in 2023, then dropped by 7.82% to $1.9 million in 2024, then increased by 4.06% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $2.1 million for Q2 2025, and $2.0 million during Q1 2025.